A Phase 3 interventional study of Eloralintide and Placebo in Osteoarthritis and Overweight or Obesity, sponsored by Eli Lilly and Company. Recruiting at 147 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 75 weeks, including screening.
2,974 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.
This study's planned enrollment of 900 is above the median of 80 across 2,240 interventional studies indexed under Osteoarthritis.
Browse Osteoarthritis studies →Eli Lilly and Company is the lead sponsor of 2,106 studies on the registry; 152 are open to participants now.
Of its 536 completed or terminated interventional studies of FDA-regulated products, 357 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have osteoarthritis of the knee and at least one of the following conditions:
Exclusion Criteria:
Have had within 90 days prior to screening:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive eloralintide subcutaneously (SC)
Drug: Eloralintide
Participants will receive placebo SC
Drug: Placebo
Participants will receive eloralintide SC
Drug: Eloralintide
Participants will receive placebo SC
Drug: Placebo
Administered SC
Also known as: LY3841136
Placebo administered SC
Percent Change from Baseline in Body Weight
Percent Change from Baseline in Body Weight
Time frame: Baseline, Week 64
Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score
Change from Baseline in the WOMAC Pain Subscale Score
Time frame: Baseline, Week 64
Change from Baseline in Systolic Blood Pressure (SBP)
Change from Baseline in SBP
Time frame: Baseline, Week 64
Percent Change from Baseline in Triglycerides
Percent Change in Baseline in Triglycerides
Time frame: Baseline, Week 64
Change from Baseline in Short Form-36 (SF-36 v2) Acute Form Physical Functioning Domain Score
Change from Baseline in SF-36 v2 Score
Time frame: Baseline, Week 64
Percent Change from Baseline in High Sensitivity, C-reactive Protein (hsCRP)
Percent Change from Baseline in hsCRP
Time frame: Baseline, Week 64
Change from Baseline in the WOMAC Physical Function Subscale Score
Change from Baseline in the WOMAC Physical Function Subscale Score
Time frame: Baseline, Week 40, Week 64
Change from Baseline WOMAC Pain Subscale Score
Change from Baseline WOMAC Pain Subscale Score
Time frame: Baseline, Week 40
Change from Baseline in Distance Walked During the 6-Minute Walk Test
Change from Baseline in Distance Walked During the 6-Minute Walk Test
Time frame: Baseline, Week 64
Change from Baseline in Body Mass Index (BMI)
Change from Baseline in BMI
Time frame: Baseline, Week 64
Change in Medication Use
Change in Medication Use
Time frame: Baseline, Week 64
Change from Baseline in SF-36v2 Acute Form Domain Scores With Exception of the Physical Functioning Domain Score
Change from Baseline in SF-36v2 Acute Form Domain Scores With Exception of the Physical Functioning Domain Score
Time frame: Baseline, Week 64
Change from Baseline in Health Status EQ-5D-5L Health State Utility
Change from Baseline in Health Status EQ-5D-5L Health State Utility
Time frame: Baseline, Week 64
Percent Change from Baseline in Fasting Insulin
Percent Change from Baseline in Fasting Insulin
Time frame: Baseline, Week 64
Percent Change from Baseline in Total Cholesterol
Percent Change from Baseline in Total Cholesterol
Time frame: Baseline, Week 64
Change from Baseline in Waist Circumference
Change from Baseline in Waist Circumference
Time frame: Baseline, Week 64
Percent Change from Baseline in Hemoglobin A1c (HbA1c)
Percent Change from Baseline in HbA1c
Time frame: Baseline, Week 64
Change from Baseline in WOMAC Stiffness Subscale Score
Change from Baseline in WOMAC Stiffness Subscale Score
Time frame: Baseline, Week 64
Change from Baseline in WOMAC Total Score
Change from Baseline in WOMAC Total Score
Time frame: Baseline, Week 64
Achievement of Improved Categorical Shift in Patient Global Impression of Severity (PGIS) - Target Knee Pain
Achievement of Improved Categorical Shift in PGIS - Target Knee Pain
Time frame: Baseline, Week 64
Achievement of Improved Categorical Shift in Patient Global Impression of Severity (PGIS) - Target Knee Function
Achievement of Improved Categorical Shift in PGIS - Target Knee Function
Time frame: Baseline, Week 64
Change from Baseline in Average Pain Intensity Numeric Rating Scale (API-NRS) Score
Change from Baseline in API-NRS Score
Time frame: Baseline, Week 64
Change from Baseline in Worst Pain Intensity Numeric Rating Scale (WPI-NRS) Score
Change from Baseline in WPI-NRS Score
Time frame: Baseline, Week 64
Pharmacokinetics (PK): Maximum Concentration at Steady State (Cmax, ss)
PK: Cmax, ss
Time frame: Baseline through Week 64
PK: Area Under the Concentration Versus Time Curve for One Dosing Interval at Steady State (AUC(0-T)ss)
PK: AUC(0-T)ss
Time frame: Baseline through Week 64
Number of Participants with Allowed Concomitant Pain Medication
Number of Participants with Allowed Concomitant Pain Medication
Time frame: Baseline, Week 64
Showing the first 100 of 147 sites across 13 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication or approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eloralintide